Resveratrol does not benefit patients with non-alcoholic fatty liver disease

Chachay, Veronique S., Macdonald, Graeme A., Martin, Jennifer H., Whitehead, Jonathan P., O’Moore-Sullivan, Trisha M., Lee, Paul, Franklin, Michael, Klein, Kerenaftali, Taylor, Paul J., Ferguson, Maree, Coombes, Jeff S., Thomas, Gethin P., Cowin, Gary J., Kirkpatrick, Carl M. J., Prins, Johannes B. and Hickman, Ingrid J. (2014) Resveratrol does not benefit patients with non-alcoholic fatty liver disease. Clinical Gastroenterology and Hepatology, 12 12: 2092-2103.e6. doi:10.1016/j.cgh.2014.02.024

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ327406_OA.pdf Full text (open access) application/pdf 619.75KB 0

Author Chachay, Veronique S.
Macdonald, Graeme A.
Martin, Jennifer H.
Whitehead, Jonathan P.
O’Moore-Sullivan, Trisha M.
Lee, Paul
Franklin, Michael
Klein, Kerenaftali
Taylor, Paul J.
Ferguson, Maree
Coombes, Jeff S.
Thomas, Gethin P.
Cowin, Gary J.
Kirkpatrick, Carl M. J.
Prins, Johannes B.
Hickman, Ingrid J.
Title Resveratrol does not benefit patients with non-alcoholic fatty liver disease
Journal name Clinical Gastroenterology and Hepatology   Check publisher's open access policy
ISSN 1542-3565
Publication date 2014-02-25
Year available 2014
Sub-type Article (original research)
DOI 10.1016/j.cgh.2014.02.024
Open Access Status File (Author Post-print)
Volume 12
Issue 12
Start page 2092
End page 2103.e6
Total pages 18
Place of publication Maryland Heights, MO, United States
Publisher W.B. Saunders
Language eng
Formatted abstract
BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD), characterized by accumulation of hepatic triglycerides (steatosis), is associated with abdominal obesity, insulin resistance, and inflammation. Although weight loss via calorie restriction reduces features of NAFLD, there is no pharmacologic therapy. Resveratrol is a polyphenol that prevents high-energy diet-induced steatosis and insulin resistance in animals by up-regulating pathways that regulate energy metabolism. We performed a placebo-controlled trial to assess the effects of resveratrol in patients with NAFLD.
METHODS: Overweight or obese men diagnosed with NAFLD were recruited from hepatology outpatient clinics in Brisbane, Australia from 2011 through 2012. They were randomly assigned to groups given 3000 mg resveratrol (n [ 10) or placebo (n [ 10) daily for 8 weeks. Outcomes included insulin resistance (assessed by the euglycemic-hyperinsulinemic clamp), hepatic steatosis, and abdominal fat distribution (assessed by magnetic resonance spectroscopy and imaging). Plasma markers of inflammation, as well as metabolic, hepatic, and antioxidant function, were measured; transcription of target genes was measured in peripheral blood mononuclear cells. Resveratrol pharmacokinetics and safety were assessed.
RESULTS: Eight-week administration of resveratrol did not reduce insulin resistance, steatosis, or abdominal fat distribution when compared with baseline. No change was observed in plasma lipids or antioxidant activity. Levels of alanine and aspartate aminotransferases increased significantly among patients in the resveratrol group until week 6 when compared with the placebo group. Resveratrol did not significantly alter transcription of NQO1, PTP1B, IL6, or HO1 in peripheral blood mononuclear cells. Resveratrol was well-tolerated.
CONCLUSIONS: Eight weeks administration of resveratrol did not significantly improve any features of NAFLD, compared with placebo, but it increased hepatic stress, based on observed increases in levels of liver enzymes. Further studies are needed to determine whether agents that are purported to mimic calorie restriction, such as resveratrol, are safe and effective for complications of obesity.
Keyword NAFLD
Obesity-related fatty liver
Chronic disease
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Published online 25 February 2014

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 55 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 81 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 01 Apr 2014, 02:38:49 EST by Dr Gethin Thomas on behalf of UQ Diamantina Institute